Jason Karlawish
speaker
1,378 appearances
5 recordings
1 series
first heard Feb 2021
last heard Dec 2023
Jason Karlawish’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
I mean it causes microbleeds in the brain.
And uh it causes uh swelling, uh edema uh as well.
And those risks are more likely in people who carry one copy of the APOE four gene, and they're even more likely in people who have two copies of the APOE four gene.
And so you have this difficult situation of a drug
That has uh well documented, well quantified risks.
Um, in particular in people who carry a gene that's associated with developing the disease.
Ам the force plot data showed a dose.
Декримент о рес то друг.
For each copy of the gene you had.
So if you were homozygote.
You had less evidence of benefit.
than if you were a ho heterozygote or a non carrier.
My takeaway from that is not that the drug quote doesn't benefit homozygotes or heterozygotes.
I I I think that's an overread of the forest plots.
But it's pretty suggestive that and this is a little this is gonna need some teasing out that if you are a ho a carrier
your potentially might not benefit as much and
And
Um you face a greater chance of these risks.
And so I think that does make for a Gordian knot of a very ethically challenged risk benefit balance uh that a patient's gonna face.
Again, my view on that is the patient and their family
Showing 641–660 of 1,378 · page 33 of 69
← Previous
Next →